Fig. 7From: Artificial intelligence learning landscape of triple-negative breast cancer uncovers new opportunities for enhancing outcomes and immunotherapy responsesThe drug responses between two MLIIC signature score groups. (A) CMap-based drug prediction. (B) Box plot shows the GDSC-based drug prediction. (C) Dot plot and box plot show the CTRP-based drug prediction. (D) Dot plot and box plot shows the PRISM-based drug predictionBack to article page